Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| HSBC Holdings | 1.91% | $14.89M | £189.68B | 54.07% | 79 Outperform | |
| Barclays | 1.40% | $10.89M | £57.54B | 59.44% | 76 Outperform | |
| ING GROEP | 1.28% | $9.98M | €65.72B | 49.00% | 61 Neutral | |
| Novartis AG | 1.27% | $9.86M | CHF198.73B | 13.86% | 78 Outperform | |
| ― | 1.24% | $9.64M | ― | ― | ― | |
| Standard Chartered | 1.21% | $9.42M | £36.74B | 85.37% | 75 Outperform | |
| GlaxoSmithKline | 1.15% | $8.93M | £71.68B | 37.12% | 77 Outperform | |
| Murata Manufacturing Co | 1.13% | $8.78M | ¥5.73T | 31.31% | 68 Neutral | |
| Roche Holding AG | 1.09% | $8.50M | CHF229.33B | 28.56% | 73 Outperform | |
| ― | 1.04% | $8.06M | ― | ― | ― |